OR WAIT 15 SECS
The WIRB-Copernicus Group announced it has formed a new cancer-focused institutional review board, WCG Oncology.
The WIRB-Copernicus Group (WCG), a provider of regulatory and ethical review services for clinical research, announced it has formed a new cancer-focused institutional review board, WCG OncologyTM. WCG Oncology features its Expert Advisory Board, which provides strategic counsel to WCG regarding the changing oncology research landscape, covering cutting-edge theory, scientific methods, technologies, and study designs.
WCG is creating this group because it is a fast-evolving medical fields--featuring advances in gene therapy, targeted treatments, and companion diagnostics. In the past four years, WCG has reviewed more than 4,000 oncology protocols, which have substantially increased in complexity.
WCG Oncology is constituted by three dedicated IRB panels, which focus wholly on the ethical oversight of oncology research, and a cadre of expert oncological specialists to assist in the review of complex and scientifically-challenging research.
Read the full release here.